Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin's Legal Appeal Part 2 - The First Argument From Objective Indicia

While Amarin Corp. (NASDAQ: AMRN) investors await the outcome of a crucial patent lawsuit, Wall Street analysts have a positive view on the stock.

Will Amarin Stock’s Fundamentals Outweigh Patent Trial?

Record revenues, international growth, and a potential legal strategy may provide upside.

Is Amarin Stock a Buy?

Amarin's Legal Appeal Part I - An Introductory Article Discussing Timeline And Valuation Scenarios

First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses

VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study

Amarin Corp. PLC (NASDAQ: AMRN) shares absolutely fell off a cliff in late March, but the stock price has gradually pushed higher since then.

Huge Sales Growth Brightens Future for Amarin Stock

Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S.

Why an Appeals Court May Hold Key to Amarin Stock Future

As of late, it has definitely been a great time to be an investor in Amarin.

Amarin's Shares March Higher, Can It Continue?

Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.

Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat

Amarin Corporation plc (AMRN) CEO John Thero on Q1 2020 Update - Earnings Call Transcript

Amarin's (AMRN) first quarter earnings were in line with expectations. However, sales beats estimates.

Amarin (AMRN) Meets Earnings Estimates in Q1, Revenues Tops

Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

Last week, Dublin-based Amarin Corp. PLC (NASDAQ: AMRN) released preliminary first-quarter sales figures for its synthetic fish-oil product.

Can Amarin Stock Overcome COVID-19 and Legal Headwinds?

Atara Biotherapeutics

Amarin and Atara Biotherapeutics could both be diamonds in the rough.

2 Top Biotech Stocks Under $10

Amarin Is A Buy Based On Vascepa's Potential In Europe

Amarin: Reassessing The Bull Thesis After Court Decision

Aurinia Pharmaceuticals

Could both of these volatile stocks be winners in the long run?

Better Buy: Amarin vs. Aurinia Pharmaceuticals

Did investors overreact to its invalidated patents?

Can Amarin's Stock Recover From Its 70% Implosion?

Amarin Corp. (NASDAQ: AMRN) is currently stuck in a tough predicament, and not just as a function of the stock market as a whole.

Is Amarin Stock Doomed After Court Ruling?

Novavax

Vertex Pharmaceuticals

Should You Buy Biotech Stocks Right Now?

Amarin's Earnings Call: Some Salient Points

Amarin Corporation plc (AMRN) CEO John Thero on Q1 2020 Results - Earnings Call Transcript

Investors who picked up the battered shares of Amarin Corp. (NASDAQ:AMRN) at the end of March are looking pretty smart.

Amarin Shares Recover Somewhat After US Patent Setback

Amarin's shares continue to rebound after last month's steep drop.

Why Amarin Stock Is on the Mend Today

Amarin Corportion Plc: Now Compelling On Ex-U.S. Opportunity And Potential Barriers To Generic Competition

News for Amarin Corporation Plc Stock (AMRN)